







Originally published as: 
 
Baune, B.T., Neuhauser, H., Ellert, U., Berger, K. 
The role of the inflammatory markers ferritin, transferrin and fibrinogen in the relationship 
between major depression and cardiovascular disorders - The German Health Interview and 
Examination Survey 












































The role of the inflammatory markers ferritin, transferrin 
and fibrinogen in the relationship between major 
depression and cardiovascular disorders – The German 
Health Interview and Examination Survey 
 
B. T. Baune1, H. Neuhauser2, U. Ellert2, K. Berger3 
 
1Department of Psychiatry and Psychiatric Neuroscience, School of Medicine and Dentistry, James Cook University, Qld, 
Australia 
2Robert-Koch Institute, Berlin, Germany 




Objective: To determine levels of inflammation (ferritin, transferring and fibrinogen) in major 
depression (MDD) and comorbid cardiovascular disease (CVD) in an adult population. 
 
Method: In 4181 participants of the German Health Interview and Examination Survey MDD was 
assessed through the Composite International Diagnostic Interview (CIDI). Coronary heart disease, 
stroke, and hypertension were diagnosed by a computer-assisted physician interview. Analyses were 
performed using anova models stratified for gender. 
 
Results: Ferritin, transferrin and fibrinogen levels showed opposing patterns in individuals with either 
CVD or MDD alone. In comorbidity analyses, male participants with MDD plus comorbid CHD or 
hypertension had lower levels of ferritin and lower fibrinogen levels in hypertension compared to men 
without MDD, while in women, results were inconsistent. 
 
Conclusion: Opposing patterns of inflammatory markers in CVD or MDD alone were reversed when 



































Major depression (MDD) is a highly prevalent disorder in the general population and a large proportion 
of patients with frequent medical diseases, such as cardiovascular disease (CVD) or cancer, suffer 
from depressive disorders. Almost half of the latter can be classified as major depression (1). Among 
patients with CVD the prevalence of depression among those with coronary heart disease is 16% to 
23% (2) and high incidences and prevalence rates of affective disorders are also observed in 
individuals with chronic heart failure or stroke (3, 4).  
A variety of hypotheses have emerged over past years suggesting biological mechanisms by which 
depression might increase the risk of cardiovascular disease (5). A frequently cited hypothesis 
describes a chronic inflammation process as the biological explanation for a relationship of coronary 
heart disease and depression (6–8). Most prior studies addressing this inflammation process analysed 
the C-reactive protein as a biomarker of inflammation. However, other biomarkers, such as ferritin, 
transferrin and fibrinogen, have also been suggested to be involved in systemic inflammation. 
Important determinants of the inflammatory process are the release of cytokines and alterations of the 
iron metabolism characterized by decreased serum iron (Fe) and transferrin (Tf) levels with normal or 
increased ferritin levels (9, 10). Inflammation and alterations in iron metabolism seem to be closely 
related, since iron is involved in inflammation through free radical production with subsequent 
decrease of serum iron (11).  
Previous studies in individuals with CVD found that coronary heart disease is related to increased 
levels of fibrinogen (12) and decreased levels of transferrin (13). Ferritin may also be increased in 
CVD (14) and cardiovascular risk factors (15, 16), but findings have been inconsistent (17–20). Prior 
studies in patients with depression suggested that systemic, low-grade inflammation plays a role in the 
onset and the course of the disease (21). Increased fibrinogen (22) and ferritin (23) and decreased 
transferrin serum levels (23) as markers of inflammation have been related to MDD. Furthermore, 
genes promoting inflammation have been involved in the pathogenesis of MDD (22).  
Since most of these studies were performed in clinical patient samples with more severe forms of 
MDD and ⁄ or CVD conditions, it is not known, if levels of these inflammation markers are also related 
to milder forms of MDD and CVD. Studies in the general population have the potential advantages to 
capture milder forms of MDD and 
CVD and to analyse different cardiovascular diseases in the same setting and the same time. 
 
 
Aims of the study 
 
Aim of this study was to determine levels of three markers of inflammation (fibrinogen, ferritin, 
transferrin) in individuals with and without MDD and three cardiovascular conditions (coronary 
heart disease, stroke or hypertension). It was hypothesized that the inflammatory markers ferritin 
and fibrinogen were increased and transferring decreased in individuals with MDD or CVD only 








The German Health Interview and Examination Survey consisted of a core survey (GHS-CS) and 
several supplemental surveys including the Mental Health Supplement (GHS-MHS). The study was 
commissioned by the German Ministry of Research, Education and Science (BMBF) and approved by 
the relevant institutional review board and ethics committee. Its sample was a stratified random 
sample from 113 communities throughout Germany with 130 sampling units (random sampling steps: 
1. selection of communities, 2. selection of sampling units, and 3. selection of inhabitants from 
population registries). Data collection was done between October 1997 and March 1999. The 
response rate of the core survey was 61.4% (n = 7124). Of the non-responders, 1860 (41%) did at 
least fill out a short questionnaire for a non-responder-analysis (gender, age, educational level, self-
rated subjective health status, smoking status). There were no significant differences between these 
and the sample with regard to gender and age (exception: 70–79 year old women; but these were not 
eligible for the mental health part, see below) and to self-rated subjective health status and smoking 
status, but there was a tendency to have a lower educational level in the non-responders. Thus, the 
sample of the core survey up to 65 years (N = 6159) was regarded as sufficiently representative to be 
utilised as a starting sample for the mental health supplement (GHS-MHS). 
  
A screening questionnaire for mental disorders with eleven questions representing essential DSMIV 
and ICD-10 criteria (CID-S) (24) had been administered at the end of the medical examination of the 
core survey. All of the participants from the core survey who answered at least one of these items with 
yes (screen positives) and a random sample of the 50% of the participants who answered all 
screening questions in the negative (screen negatives) were included in the mental health 
supplement. Non-response did not differ between screen-negative and screen-positive respondents 
from the core survey. To account for the over-sampling of screen positives and for differential non-
response among subgroups, data were weighted by selection probabilities and demographic 
characteristics (age, gender, and region) in the later analyses.  
Respondents of the core survey older than 65 years were excluded from the GHS-MHS because the 
psychometric properties of the CIDI, the interview used in the study, have not yet been satisfactorily 
established for use in older populations (25). The conditional response rate of the GHS-MHS was 
87.6%, resulting in a total of n = 4181 respondents (out of the eligible n = 4775) who completed the 
mental health assessment. Sociodemographic characteristics of this sample matched the German 
general population aged 18–65 years in terms of age, gender and social status. The presented 
(weighted) results can be regarded as representative with regard to age, gender and East-West 
Germany distribution for the German non-institutionalized adult population from 18 to 65 years of age 
with sufficient language skills to follow the interviews. Written informed consent was obtained for both 
surveys. Participants did not get any financial compensation for their study participation. A full 
description of the study methodology and sampling can be found elsewhere (24, 26). 
 
 
Assessment of cardiovascular diseases 
 
The core survey consisted of (1) a self-report questionnaire, (2) a standardized computerassisted 
medical interview, (3) anthropometric and blood pressure measurements and the collection of blood 
and urine samples, and (4) a screening for mental disorders, which served as the first stage of the 
GHS-Mental Health Survey (MHS). All examinations and interviews were done in study centres at the 
respective sample points throughout Germany. The self-report questionnaire evaluated the subjects_ 
current and past physical symptoms and complaints, health care utilization, and impairments and 
disabilities. Completion of this questionnaire was followed by a face to face computer assisted medical 
interview by a study physician who inquired about previous physician diagnoses (27, 28). 
Given the cross-sectional study design all respondents with medical diseases were survivors of any 
previous life threatening events, e.g. myocardial infarction or stroke, including those having had 
revascularisation procedures. No estimations of the prevalence of CVDs among non-survivors were 
available (27, 28). This analysis was restricted to three diagnostic groups, hypertension, coronary 
heart disease and stroke. Blood pressure was measured during the examination by means of 
three consecutive measurements allowing for 3 min intervals between each measure. According to the 
WHO guidelines hypertension was defined as systolic blood pressure ‡140 mmHg and diastolic 
blood pressure ‡90 mmHg (29). All three measures had to be above either diastolic or systolic or both 
criteria to qualify as hypertensive. Participants with the previous diagnosis of hypertension, but normal 
blood pressure were considered as hypertensive. Coronary heart disease comprises participants 
with previous ischemic heart disease, previous non-fatal myocardial infarction or heart failure. Stroke 
included all major stroke types and transitory ischemic attacks (30). 
Social status was classified into three strata (low, medium, and high social status), through use of the 
Winkler Social Index. The latter includes information about income, education, and current occupation 
and yields a summary score ranging from 3 to 21 points. Established cut-offs were then used to 
categorize individuals into the three social strata (low, medium, high). The Winkler Social Index is a 
well established score applied to several National Surveys in Germany (31). 
 
 
Assessment of mental disorders 
 
Psychopathological and diagnostic assessments were based on the computer-assisted version of the 
Munich Composite International Diagnostic Interview. The DIA-X ⁄M-CIDI is a modified version of the 
World Health Organization CIDI, version 2.1 (32), supplemented by questions to cover DSM-IV and 
ICD-10 criteria. The DIAX ⁄M-CIDI is a fully structured interview that allows for the assessment of 
symptoms, syndromes, as well as 4-week, 12-months and lifetime diagnoses of DSM-IV mental 
disorders. With regard to Major Depression (MDD) reliability and validity of this instrument is good to 
very good. Details of the psychometric properties of the CIDI are reported elsewhere (33). MDD was 
used as a lifetime categorisation. We additionally analysed single episode MDD and recurrent MDD 
  
separately to detect potential dose-response relationships. Most interviews of the mental health 
assessment were done within 2 to 4 weeks after the core survey medical examination at the homes of 
the respondents (average duration: 63 min) by study doctors specifically trained in the use of the 






Blood drawing followed a standard protocol, fasting time was recorded and all laboratory tests were 
performed in a central laboratory. The Microparticles-Enzyme-Immunoassay (MEIA) from Abbot was 
used to measure ferritin, whereas the Nephelometry method from Siemens was used to measure 





All laboratory parameters (ferritin, transferrin, and fibrinogen) were log-transformed to achieve normal 
distribution of the data. Mean values of the three log-transformed markers were first compared across 
categories of sociodemographic and disease categories using linear regression (in case of more than 
two categories) or Student_s T-Test (in case of only two categories). In these models the respective 
inflammatory marker was the dependent variable. Further analyses were carried out stratified for men 
and women, and for CVD type using adjusted means from Analysis of Variance (anova) models. In 
these models means of each biomarker were compared between participants with and without MDD 
after adjustment for age, social status, body mass index, smoking status and alcohol consumption. 
Analyses were performed by use of spss (version 15.0), which includes procedures for the analysis of 








In total, 4181 participants aged 18–65 years were assessed for mental health disorders. About 49.7% 
of the sample were women, mean age of all participants was 43.5 years (min 18; max 65; SD 11.6). 
The overall lifetime prevalence of major depression was 14.8%. It was significantly higher in women as 
compared to men (20.7% vs. 8.9%; P = 0.0005). Single lifetime episodes of major depression were 
diagnosed in 9.3% (n = 388) of the participants whereas the prevalence of recurrent MDD was 5.5% (n 
= 231).  
Of the total study population, 18.4% were classified as hypertensive while prevalence rates of 
CHD and stroke were 4.9% and 1.5% respectively. MDD was more frequent among participants with, 
compared to those without, any of the three examined types of CVD (CHD 6.7% vs. 4.6%, P = 0.041; 
stroke 2.7% vs. 1.2%, P = 0.006; hypertension 19.6% vs. 18.2%; P = 0.43). Ferritin, transferrin and 
fibrinogen levels across the sample Table 1 presents log-transformed ferritin, transferring and 
fibrinogen levels according to sociodemographic variables and MDD and CVD status. While ferritin 
and fibrinogen levels increased with age, transferrin decreased in higher age groups. Men had higher 
ferritin values as compared to women, whereas transferrin and fibrinogen were significantly higher in 
female than in male participants. Social status was significantly related to transferrin and fibrinogen 
levels.  
Participants with MDD had lower ferritin levels (log-transformed mean, 4.08 vs. 4.2; P = 0.003), 
transferrin levels (1.03 vs. 1.05; P = 0.056) and fibrinogen levels (1.02 vs. 1.05; P = 0.009) if no 
stratification for CVD status was done, compared to those without MDD. A different pattern emerged 
for the same analyses in participants with CVDs, again without stratification for MDD status. While 
ferritin did not vary between those with and without any of the three CVDs (4.2 vs. 4.1; P = 0.15), both 
other markers were significantly increased in participants with CVD as compared to those without 
(transferrin 1.07 vs. 1.03, P = 0.0005; and fibrinogen 1.06 vs. 1.03, P = 0.002). 
Additional stratification for type of CVD (Table 1) showed that the presence of coronary heart disease 
was related to lower ferritin levels and higher transferrin levels. Hypertension was associated with 
higher levels of all three markers, while no significant variation of any marker with the presence of 
stroke was observed. Ferritin, transferrin and fibrinogen in men and women Further analyses were 
carried out to compare levels of inflammatory markers according to MDD status and comorbidity with 
  
CHD, stroke and hypertension These results are presented in Table 2. In men, MDD was related to 
significantly lower ferritin values in participants with either CHD or hypertension, but not with stroke. In 
contrast, ferritin levels in women were not different among those with or without MDD across all types 
of CVD. Transferrin levels showed no significant differences according to MDD status in any of the 
examined CVD types in men. Levels were significantly lower in hypertensive women with MDD 
compared to non-depressive women with hypertension. Fibrinogen levels were lower in men with 
MDD and any of the three CVDs, compared to those without MDD. However, the difference was only 
statistical significant in those with hypertension. In women fibrinogen levels were not related to the 
comorbid situation.  
Finally, when testing a potential dose-response relationship between the frequency of MDD episodes 
and levels of inflammatory markers, we found no stronger effect of recurrent MDD 





In this analysis we examined levels of the inflammatory markers ferritin, transferrin and fibrinogen in 
the comorbid relation between MDD and three frequent types of cardio- ⁄ cerebrovascular diseases in 
an adult general population. MDD was related to lower levels of all three markers, while CVD was 
associated with higher levels. In the comorbid situation with both conditions present MDD was, with 
one exception, associated with lower levels of the three inflammation markers in both genders. 
However, not all differences were statistically significant. MDD was significantly related to lower ferritin 
levels in male participants with a history of CHD and hypertension and to lower fibrinogen levels in 
men with hypertension. In women MDD was related to lower transferring levels in women with 
hypertension only.  
Our findings contribute to the emerging literature on the role of inflammation in the relationship 
between CVD and MDD (35, 36). However, no previous study has particularly analysed ferritin, 
transferrin and fibrinogen in this relationship. Recent gender-specific analyses support the 
inflammation hypotheses for CVD and comorbid depression. A recent study in women investigating 
inflammatory markers in the relationship between suspected coronary ischemia and depression found 
a robust association of CRP levels with depression, although inflammatory biomarkers explained only 
a small portion of the association between depression and CVD incidence (37). On a similar note, 
while a recently published prospective study found evidence of a positive association between 
depressive symptoms and risk of incident stroke, inflammation, measured through CRP at baseline, 
did not appear to mediate the relationship between depressive symptoms and stroke (38). Studies 
investigating other inflammatory markers such as ferritin, transferrin, fibrinogen and cytokines are 
warranted to further elucidate the relationship between CVD and comorbid MDD.  
Our findings on CVD alone are in confirmation of a study by Tseke et al. (39) reporting increased 
levels of fibrinogen in CVD, which was interpreted as an expression of chronic inflammation in CVD. In 
addition, we confirmed that transferrin may be increased in coronary heart disease as previously 
reported (40). The involvement of transferrin in chronic inflammation is theoretically explained through 
prohibiting iron from participating in oxidative reactions in systemic inflammation; however, transferrin 
has also been found to promote free radical damage and thus enhancing systemic inflammation (11). 
In our analysis, MDD alone was related to lower ferritin and fibrinogen levels. A recent report by 
Whooley et al. (41) showed that depression was associated with lower levels of fibrinogen in 
outpatients with CHD, which could not be confirmed by our analysis either in men or women. Our 
finding on decreased ferritin is contradicting earlier studies that reported normal or increased ferritin 
levels in depression (9, 10). This finding might be related to milder forms of MDD included in a general 
population sample in our study as compared to more severe cases of depression in clinical samples. 
Finally, a dose-response relationship hypothesizing that recurrent MDD had stronger effects on 
inflammatory marker levels than single MDD as compared to no MDD was not found in this analysis. 
Our study has strengths and limitations. The study in the general adult population allowed for gender-
specific analyses of various types of cardiovascular diseases and single and recurrent MDD applying 
the same study framework. Among the limitations is the cross-sectional study design, that does not 
allow to draw conclusions on the time course and causative effect of inflammatory markers in the 
relationship between CVD and MDD. Other inflammatory markers such as cytokines are also of in 
interest for this research. In addition, since the cardiovascular disorders were partly based on self-
report, the risk of misdiagnoses 
might have been introduced despite the verification of the medical diagnoses by a qualified physician. 
Finally, the time gap of 2–4 weeks between the blood samples and the mental health assessment 
might have introduced some bias in the association between blood parameters and depression or 
CVDs. Since the investigated blood parameters such as ferritin and transferrin reflect longer-term 
  
rather than acute changes in the iron metabolism, it is assumed that this potential bias is minor in our 
study. However, future cross-sectional studies should aim for the simultaneous assessment of blood 
parameters and mental health diagnoses.  
In conclusion, our findings support a genderspecific role of the inflammatory markers of ferritin, 
transferrin and fibrinogen in the relationship between CVD and MDD. MDD reduced levels of the three 
inflammation markers in individuals with CVD as opposed to levels of inflammatory markers in CVD 
unstratified for MDD. Gender-specific analyses and stratification for CVD diagnoses and MDD status is 
necessary to detect the opposing patterns in inflammatory marker levels in the relationship between 
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Table 1. Ferritin, transferrin and fibrinogen across the sample ‡ (n = 4181) 
 
 
†Geometric mean (log-transformed marker); CHD, coronary heart disease; MDD, single ⁄ recurrent major depressive disorder. 
‡P-values adjusted for age, social status and gender were appropriate for the comparison of inflammatory markers among 



























Table 2. Ferritin, transferrin and fibrinogen in men and women† 
 
 
* Geometric mean (log-transformed marker); CHD, coronary heart disease; MDD, major depressive disorder. 
† Adjusted for age, social status, body mass index, smoking status, alcohol consumption; P-values from ANOVA models for the 
comparison MDD yes vs. no. 
  
